Brinzolamide

Brinzolamide

Catalog Number:
L002369158APE
Mfr. No.:
APE-A4359
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Brinzolamide is a potent and selective inhibitor of carbonic anhydrase type II (CA II) with IC50 value of 3.19nM [1].Brinzolamide is the newest topical CAI to be successfully developed and marketed. It is a safe and efficacious glaucoma drug. In the in vitro assay, brinzolamide has its highest affinity (Ki of 0.13nM) and inhibitory potency (IC50 of 3.19 nM) for CA-II. It has much higher affinity and greater potency for CA-II than for CA-I and CAIV. In the in vivo models, administration of brinzolamide significantly reduces the intraocular pressure (IOP) both in the pigmented rabbits and cynomolgus monkeys with ocular hypertension induced by argon laser trabeculoplasty [1]. As an inhibitor of CA, brinzolamide is also used to assess cerebral blood flow reserve as it can conserve CO2 in the tissues, and the CO2 can then act on blood vessels and produce vasodilatation. Moreover, brinzolamide is proved to be safe and efficacious for reducing intraocular pressure [1].

          [1] DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29.

      • Properties
        • Alternative Name
          (4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
          CAS Number
          138890-62-7
          Molecular Formula
          C12H21N3O5S3
          Molecular Weight
          383.51
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          insoluble in H2O; ≥15.05 mg/mL in DMSO; ≥8.82 mg/mL in EtOH with gentle warming and ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Michaela T. Reichmann, Liku B Tezera, et al. "Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets." J Clin Invest. 2021 Aug 2;131(15):e148136. PMID:34128839

    We Also Recommend

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.